Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group

Antzeko izenburuak

• Shorter-Duration Therapy Using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide With or Without Radiotherapy for Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group
  nork: Walterhouse, David O., et al.
  Argitaratua: (2014)
• Local Control and Outcome in Children with Localized Vaginal Rhabdomyosarcoma: A Report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group
  nork: Walterhouse, David O., et al.
  Argitaratua: (2011)
• Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group
  nork: Beverly Raney, R., et al.
  Argitaratua: (2011)
• Treatment Approach and Outcomes in Infants with Localized Rhabdomyosarcoma: A Report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group
  nork: Bradley, Julie A., et al.
  Argitaratua: (2018)
• Prevalence and Clinical Impact of Anaplasia in Childhood Rhabdomyosarcoma: A Report from the Soft Tissue Sarcoma Committee for the Children’s Oncology Group
  nork: Qualman, Stephen, et al.
  Argitaratua: (2008)